The majority of Teva's business lies in generic and off-patent branded drugs and faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...
A spokesperson added that “it would not be accurate to point to cost as the sole driver of any sourcing decision.” Previously P&G bought mostly pricier ... has mainly supplied non-U.S. markets, an ...